Gecacitinib before, during, and after stem cell transplant for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether taking the study drug gecacitinib (a JAK inhibitor, which helps control blood cell counts and symptoms) before, during, and after a stem cell transplant improves outcomes for people with myelofibrosis. The goal is to see if it can make the transplant safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with primary myelofibrosis, or myelofibrosis after polycythemia vera, or after essential thrombocythemia
- Your disease is considered intermediate or high risk
- You are scheduled to receive a stem cell transplant from a matched or partially matched donor
- You are in good enough health to carry out daily activities (ECOG score of 0-2 and Karnofsky score at least 60%)
- You have not had a stem cell or organ transplant before, and your disease has not progressed to a more aggressive phase
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called gecacitinib for people whose chronic graft-versus-host disease (a condition where donor cells attack their body after a stem cell transplant) has not gotten better with steroids. The drug aims to control the disease and help you feel better.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.